On January 23, 2026, Tigress Financial raised its 12-month price target for Walmart to $135, implying potential upside of 14.59%. This recommendation reflects confidence in the company’s strategic investments in omnichannel fulfillment and margin expansion through private-label growth, and represents one of the more optimistic forecasts among the 25 analysts covering the stock.

Over the past month, Walmart’s share value has climbed by 6.94%, outpacing the 4.28% gain recorded by the broader Retail‐Wholesale sector and the S&P 500’s 0.71% advance. This resilience persisted despite a modest pullback of 1.25% in the most recent session, underscoring sustained investor interest driven by strong same-store sales trends and robust holiday season results.

Investors are focusing on Walmart’s fiscal second-quarter results, due February 19, 2026, with consensus estimates calling for adjusted earnings per share of $0.73, a 10.61% increase year-over-year. Revenue is forecast at $190.04 billion, up 5.25% from the prior-year quarter, supported by higher membership fee income from Walmart+ and continued market share gains in grocery and general merchandise categories.

This spring, Walmart plans to open clinical research sites in selected former outpatient health centers and retail locations, marking its entry into decentralized clinical trials. The initiative is expected to enroll up to 50,000 participants over the next two years, leveraging in-store pharmacies and telehealth platforms to accelerate patient recruitment and data collection, and potentially generating an annualized revenue stream of $200 million by 2028.